Number of responders to polyribosylribitol phosphate (PRP) antigen Post-dose 3 (12 to 13 Months) [clinicaltrials_resource:6c7f0ce55e68c6c2efd173e54e0ff651]

Number of responders to polyribosylribitol phosphate (PRP) antigen Post-dose 3 (12 to 13 Months) [clinicaltrials_resource:6c7f0ce55e68c6c2efd173e54e0ff651]

V419 + Rotavirus vaccine + Prevenar 13
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:6c7f0ce55e68c6c2efd173e54e0ff651
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) [clinicaltrials:NCT01480258]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Number of responders to polyribosylribitol phosphate (PRP) antigen Post-dose 3 (12 to 13 Months) [clinicaltrials_resource:6c7f0ce55e68c6c2efd173e54e0ff651]

V419 + Rotavirus vaccine + Prevenar 13
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:6c7f0ce55e68c6c2efd173e54e0ff651
Bio2RDF identifier
6c7f0ce55e68c6c2efd173e54e0ff651
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:6c7f0ce55e68c6c2efd173e54e0ff651
measure [clinicaltrials_vocabulary:measure]
Number of responders to polyribosylribitol phosphate (PRP) antigen
time frame [clinicaltrials_vocabulary:time-frame]
Post-dose 3 (12 to 13 Months)
description
V419 + Rotavirus vaccine + Prevenar 13
identifier
clinicaltrials_resource:6c7f0ce55e68c6c2efd173e54e0ff651
title
Number of responders to polyri ...... Post-dose 3 (12 to 13 Months)
@en
inDataset
type
label
Number of responders to polyri ...... f0ce55e68c6c2efd173e54e0ff651]
@en